Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin (KRT-232) +/- Avelumab in Merkel Cell Carcinoma
NCT03787602Phase 2Unknown
- Sponsor
- Kartos Therapeutics
- Start
- Mar 2019
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of navtemadlin in Merkel cell carcinoma (MCC), sponsored by Kartos Therapeutics. Status: unknown.
02
Drugs
navtemadlin
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03787602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787602.